Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received U.S. FDA Breakthrough Therapy designation for optic neuritis, supported by positive Phase 2 ACUITY data and ...

Oculis Holding AG, a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced that its ...

Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for its eye disease therapy Privosegtor as a treatment for optic neuritis (ON), ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

After traumatic brain injury (TBI), some patients may recover completely, while others retain severe disabilities. Accurately evaluating prognosis is challenging in patients on life-sustaining therapy ...

There's a lot of drone warfare footage on the internet from Ukraine and Russia. But over the last year, a surprising evolution in the conflict has emerged, via photos from the battlefront posted ...

Lacey W. Heinsberg receives funding from the National Institutes of Health. Amery Treble-Barna receives funding from the National Institutes of Health. A newly discovered biological signal in the ...

Background: Optic neuritis (ON) is a common cause of visual loss in adults. It is commonly related to or occurs in the scenario of a demyelinating disease. Although treatment leads to visual recovery, ...

Lucinda Grummitt does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Traumatic brain injury, or TBI, affects millions of Americans each year, often resulting in long-term health challenges. New national recommendations are now paving the way for more effective short- ...